Amerika Serikat - Inggris - NLM (National Library of Medicine)

kadmon pharmaceuticals, llc - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 200 mg - ribasphere® (ribavirin capsules usp) in combination with interferon alfa-2b (pegylated and nonpegylated) is indicated for the treatment of chronic hepatitis c (chc) in patients 3 years of age and older with compensated liver disease [see warnings and precautions (5.9, 5.10) , and use in specific populations (8.4) ]. the following points should be considered when initiating ribasphere combination therapy with peginterferon alfa-2b or interferon alfa-2b: ribasphere combination therapy is contraindicated in: teratogenic effects pregnancy category x [see contraindications (4), warnings and precautions (5.1), and nonclinical toxicology (13.1) ]. treatment and post-treatment: potential risk to the fetus: ribavirin is known to accumulate in intracellular components from where it is cleared very slowly. it is not known whether ribavirin contained in sperm will exert a potential teratogenic effect upon fertilization of the ova. in a study in rats, it was concluded that dominant lethality was not induced by ribavirin

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

clinect nz pty limited - ribavirin 200mg;  ;   - film coated tablet - 200 mg - active: ribavirin 200mg     excipient: colloidal silicon dioxide croscarmellose sodium crospovidone magnesium stearate microcrystalline cellulose opadry white 03f180000 povidone - ibavyr is indicated in combination with other oral agents for the treatment of chronic hepatitis c (chc) in adults.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

clinect nz pty limited - ribavirin 400mg;  ;   - film coated tablet - 400 mg - active: ribavirin 400mg     excipient: colloidal silicon dioxide croscarmellose sodium crospovidone magnesium stearate microcrystalline cellulose opadry orange 04f93451 povidone - ibavyr is indicated in combination with other oral agents for the treatment of chronic hepatitis c (chc) in adults.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

clinect nz pty limited - ribavirin 600mg;  ;   - film coated tablet - 600 mg - active: ribavirin 600mg     excipient: colloidal silicon dioxide croscarmellose sodium crospovidone magnesium stearate microcrystalline cellulose opadry white 03f180000 povidone - ibavyr is indicated in combination with other oral agents for the treatment of chronic hepatitis c (chc) in adults.

Uni Eropa - Inggris - EMA (European Medicines Agency)

accord healthcare s.l.u. - eptifibatide - myocardial infarction - antithrombotic agents - eptifibatide accord is intended for use with acetylsalicylic acid and unfractionated heparin.eptifibatide accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ecg) changes and/or elevated cardiac enzymes.patients most likely to benefit from eptifibatide accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early ptca (percutaneous transluminal coronary angioplasty).

Uni Eropa - Inggris - EMA (European Medicines Agency)

teva b.v. - ribavirin - hepatitis c, chronic - antivirals for systemic use - ribavirin teva is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. ribavirin monotherapy must not be used.there is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).naïve patients adult patients ribavirin teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for hepatitis c viral ribonucleic acid hcv-rna.paediatric patients (children 3 years of age and older and adolescents) ribavirin teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, and who are positive for hcv-rna.when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. the reversibility of growth inhibition is uncertain. the decision to treat should be made on a case by case basis.previous treatment failure patientsadult patients ribavirin teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis c who have previously responded (with normalisation of alt at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

kadmon pharmaceuticals, llc - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 200 mg - ribasphere (ribavirin, usp) in combination with peginterferon alfa-2a is indicated for the treatment of patients 5 years of age and older with chronic hepatitis c (chc) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. the following points should be considered when initiating ribasphere combination therapy with peginterferon alfa-2a: ribasphere (ribavirin, usp) is contraindicated in: ribasphere and peginterferon alfa-2a combination therapy is contraindicated in patients with: teratogenic effects pregnancy: category x [see contraindications (4)] . ribavirin produced significant embryocidal and/or teratogenic effects in all animal species in which adequate studies have been conducted. malformations of the skull, palate, eye, jaw, limbs, skeleton, and gastrointestinal tract were noted. the incidence and severity of teratogenic effects increased with escalation of the drug dose. survival of fetuses and offspring was reduced [see contraindications (4) an

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - ribavirin, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; microcrystalline cellulose; crospovidone; silicon dioxide; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - ibavyr (ribavirin tablets) is indicated in combination with other oral agents for the treatment of chronic hepatitis c (chc) in adults.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

aurobindo pharma limited - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide 75 mg in 100 ml

Amerika Serikat - Inggris - NLM (National Library of Medicine)

teva parenteral medicines, inc. - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide 0.75 mg in 1 ml